Phase II trial of carboplatin/docetaxel in patients with resected NSCLC

doi:10.5320/wjr.v4.i1.1

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6376)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

402

WORD

357

HTML

2558

Figures (1-2)

223

Tables (1-4)

220

Sum=3760

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1170

Download

1446

Sum=2616

Mar 28, 2014 (publication date) through Nov 30, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Respirology

ISSN

2218-6255

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Respirol. Mar 28, 2014; 4(1): 1-7
Published online Mar 28, 2014. doi: 10.5320/wjr.v4.i1.1

Full Size Figure Download Figure

Figure 2 Overall survival. A: The 2-year overall survival (OS) rate was 88.3%; B: The OS curves stratified by pathological stage.

Citation: Uramoto H, Nakanishi R, Uchiyama A, Inoue M, Sugaya M, Iwata T, Ebi N, Hanagiri T, Tanaka F. Phase II trial of carboplatin/docetaxel in patients with resected NSCLC. World J Respirol 2014; 4(1): 1-7
URL: https://www.wjgnet.com/2218-6255/full/v4/i1/1.htm
DOI: https://dx.doi.org/10.5320/wjr.v4.i1.1